Re: Hughes et al.: Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis (Ophthalmology. 2019;126:415-424)

Ophthalmology. 2019 Oct;126(10):e75-e76. doi: 10.1016/j.ophtha.2019.04.028.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adalimumab
  • Antirheumatic Agents*
  • Arthritis, Juvenile*
  • Cost-Benefit Analysis
  • Humans
  • Uveitis*

Substances

  • Antirheumatic Agents
  • Adalimumab